Global Pulmonary Edema Therapeutics Market Regional Analysis

Amol

posted on 3 years ago — updated on 1 second ago

308
views

Pulmonary Edema Therapeutics Market

Europe may see a profitable expansion in the global pulmonary edoema therapeutics market over the forecast period as a result of increased collaborations and sales partnerships. For example, Novartis International AG, a leading pharmaceutical company, announced on November 19, 2020, an exclusive global licence and collaboration agreement with Mesoblast to develop, commercialise, and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.

Remestemcel-L is an experimental therapy that comprises of culture-expanded mesenchymal stromal cells taken from the bone marrow of an unrelated donor.

https://knackersblogger.blogspot.com/2022/09/pulmonary-edema-therapeutics-market_23.html

Amol

Working in Coherent Market Insights. Coherent Market Insights is a global market intelligence and consulting organization, focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan.